fam-trastuzumab deruxtecan-nxki for injection
for intravenous use Initial U.S. Approval: 2019
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:Metastatic Breast Cancer and Locally Advanced or Metastatic Gastric Cancer. In August, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for patients with unresectable or metastatic HER2-low breast cancer, establishing a new disease classification for breast cancer — HER2 low — and offering a new targeted agent for this patient population.
Facts about fam-trastuzumab deruxtecan-nxki
Proprietary Name: On Request
Active Ingredient(s): fam-trastuzumab deruxtecan-nxki
Dosage Forms And Strengths: For injection: 100 mg lyophilized powder in a single-dose via
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “fam-trastuzumab deruxtecan-nxki injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For fam-trastuzumab deruxtecan-nxki
Approved accessible "fam-trastuzumab deruxtecan-nxki injection"
Enhertu (fam-trastuzumab deruxtecan-nxki) intravenous infusion was originally approved in 2019. In 2022, CDER approved Enhertu to treat patients with unresectable or metastatic HER2-low breast cancer through the Accelerated Approval program. This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, a newly defined subset of HER2-negative breast cancer in which there are some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive.
Enhertu was also approved in 2022 for adults with unresectable or metastatic HER2-positive breast cancer who had received a prior anti-HER2-based regimen; as well as for adults with unresectable or metastatic non-small cell lung cancer whose tumors have an activating HER2 mutation who received prior systemic (treating the whole body) therapy.
How can 1 go about obtaining fam-trastuzumab deruxtecan-nxki injection?
If fam-trastuzumab deruxtecan-nxki injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398